A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
NCT01851746 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2013-05-10
Summary
The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
Conditions
- Recurrent Ovarian Cancer
Sponsors & Collaborators
-
Wuhan University
lead OTHER
Principal Investigators
-
Hong-bing Cai, MD,PhD · Zhongnan Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-03-31
- Primary Completion
- 2015-02-28
- Completion
- 2015-02-28
Countries
- China
Study Locations
More Related Trials
-
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
NCT00004037 ·Status: TERMINATED ·Phase: PHASE2
-
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
NCT00189371 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT01570582 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.
NCT04661696 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
NCT00657878 ·Status: UNKNOWN ·Phase: PHASE3
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03776812 ·Status: COMPLETED ·Phase: PHASE2
-
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
NCT01650376 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
NCT02026921 ·Status: COMPLETED ·Phase: PHASE2
-
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303 ·Status: RECRUITING ·Phase: PHASE3
-
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
NCT00354601 ·Status: TERMINATED ·Phase: PHASE2
-
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
NCT02440425 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
NCT00003449 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
NCT03763123 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
NCT03717415 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer
NCT02159820 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
NCT04561817 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
NCT01680575 ·Status: UNKNOWN
-
Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer
NCT04348032 ·Status: UNKNOWN ·Phase: PHASE2
-
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
NCT00189566 ·Status: COMPLETED ·Phase: PHASE2
-
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
NCT00043082 ·Status: COMPLETED ·Phase: PHASE3
-
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
NCT05310344 ·Status: UNKNOWN ·Phase: PHASE2
-
Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study
NCT07311577 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
NCT07285941 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours
NCT00189410 ·Status: COMPLETED ·Phase: PHASE2